Inactive Instrument

Analyst Reco. Alexion Pharmaceuticals, Inc.

Equities

ALXN

US0153511094

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

AstraZeneca 2Q Net Profit Dropped Despite Higher Revenue; Raises Guidance	21-07-29	DJ
ALEXION PHARMACEUTICALS : Oppenheimer Upgrades Alexion Pharmaceuticals to Outperform From Perform, $205 Price Target	21-05-05	MT
ALEXION PHARMACEUTICALS : SVB Leerink Adjusts Alexion Pharmaceuticals PT to $173 From $156, Maintains Market Perform Rating	21-05-03	MT
ALEXION PHARMACEUTICALS : SVB Leerink Downgrades Alexion Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $156 From $196	21-03-23	MT
ALEXION PHARMACEUTICALS : SVB Leerink Adjusts Price Target on Alexion Pharmaceuticals to $196 From $200, Maintains Outperform Rating	21-02-05	MT
ALEXION PHARMACEUTICALS : Raymond James Downgrades Alexion Pharmaceuticals to Market Perform from Outperform	21-01-08	MT
ALEXION PHARMACEUTICALS : Stifel Adjusts Alexion Pharmaceuticals' Price Target to $175 from $125, Keeps Hold Rating	21-01-05	MT
ALEXION PHARMACEUTICALS : Truist Securities Downgrades Alexion Pharmaceuticals to Hold From Buy; Price Target is $175	20-12-16	MT
ALEXION PHARMACEUTICALS : UBS Adjusts Price Target on Alexion Pharmaceuticals to $175 From $133 on Pending Acquisition, Maintains Neutral Rating	20-12-15	MT
ALEXION PHARMACEUTICALS : Citigroup Downgrades Alexion Pharmaceuticals to Neutral From Buy; Price Target is $175	20-12-15	MT
ALEXION PHARMACEUTICALS : Oppenheimer Downgraded Alexion Pharmaceuticals to Not Rated From Perform Following Announcement About Acquisition by AstraZeneca	20-12-14	MT
ALEXION PHARMACEUTICALS : RBC Capital Adjusts Alexion Pharmaceuticals PT to $175 From $139, Maintains Outperform Rating	20-12-14	MT
ALEXION PHARMACEUTICALS : SVB Leerink Adjusts Alexion Pharmaceuticals' Price Target to $200 From $159, Keeps at Outperform	20-12-14	MT
ALEXION PHARMACEUTICALS : Credit Suisse Downgrades Alexion to Neutral from Outperform on Sale to AstraZenica, Adjusts Price Target to $194 from $147	20-12-14	MT
ALEXION PHARMACEUTICALS : BMO Capital Downgrades Alexion Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $175 From $152	20-12-14	MT
ALEXION PHARMACEUTICALS : Baird Downgrades Alexion Pharmaceutical to Neutral From Outperform; Price Target is $175	20-12-14	MT
ALEXION PHARMACEUTICALS : Wedbush Downgrades Alexion Pharmaceuticals to Neutral From Outperform, Adjusts PT to $175 From $157 on AstraZeneca Takeout	20-12-14	MT
ALEXION PHARMACEUTICAL INC : RBC keeps its Buy rating	20-12-14	ZD
ALEXION PHARMACEUTICALS : Bernstein Starts Alexion Pharmaceuticals at Market Perform With $148 Price Target	20-11-20	MT
Wall Street closes higher after payrolls report	17-12-08	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Alexion Pharmaceuticals, Inc.

Equities

ALXN

US0153511094

Analyst Reco.

Filters